| Field | Specification |
|---|---|
| Mfr No | |
| Alternative Names | cluster of differentiation 38 cells, ADP-Ribosyl Cyclase 1 cell line, NAD(+) Nucleosidase cell line, ADPRC 1 cell line, TNFRSF17 cells, Cluster of Differentiation 19 cell lines, B-lymphocyte surface antigen B4 cells |
| Product Type | |
| Shipping | |
| Species | |
| Storage |
Scientific Background
The CD38 protein is a dimeric, non-lineage-restricted, type II transmembrane glycoprotein that synthesizes and hydrolyzes the second messengers cyclic ADP-ribose and NADP. CD38 is highly expressed by lymphoid and myeloid cells, particularly plasma cells. Increased CD38 expression on chronic lymphocytic leukemia (CLL) cells is linked to aggressive disease features and poor clinical outcome. CD38 is used as a prognostic marker for patients with CLL and multiple myeloma (MM), and is an ideal target for immunotherapy in CLL and MM.
B-lymphocyte antigen CD19 (Cluster of Differentiation 19), also known as B-Lymphocyte Surface Antigen B4 and CVID3, is a transmembrane protein expressed in follicular dendritic cells and all B lineage cells except plasma cells. CD19 plays two major roles in human B cells. It acts as an adaptor protein to recruit cytoplasmic signaling proteins to the membrane and it works within the CD19/CD21 complex to decrease the threshold for B cell receptor signaling pathways. Due to its presence on all B cells, it is a biomarker for B lymphocyte development and lymphoma diagnosis and can be used as a target for leukemia immunotherapies. CD19-targeted therapies based on T cells that express CD19-specific chimeric antigen receptors (CARs) have been utilized for their antitumor abilities in patients with CD19+ lymphoma and leukemia, such as Non-Hodgkin's Lymphoma (NHL), CLL and ALL.
Product Description
CAR-TRecombinant clonal stable CHO cell line constitutively expressing full length human CD38 protein (also known as ADPRC1, Genbank accession #NM_001775) and human CD19 protein (also known as B4 or CVID3, Genbank accession #NM_001770). This cell line was derived from our CHO-K1 Luciferase cells (BPS Bioscience, #79725), therefore it also constitutively expresses the firefly luciferase reporter. Surface expression of CD38 and CD19 were confirmed by flow cytometry.
Product Specifications
| Host Cell Line | CHO |
|---|---|
| Host Species | Hamster |
| Transfection Method | Lipofectamine 2000 |
| Supplied As | 2 vials of frozen cells. 2 x 10^6 cells in 1 ml of 10% DMSO |
| Harmonized Tariff Code | 3002-5900 |
Quality Control & Validation
✓ Mycoplasma-TestedThe cell line has been screened using the MycoAlert™ Mycoplasma Detection kit (Lonza, #LT07-218) to confirm the absence of Mycoplasma species.
Usage Notes
See assay protocol for detailed instructions.
Safety & Handling
⚠ Avoid freeze/thaw cycles.
Regulatory Information
License Disclosure
Related Products
Related Products: Cat. #60690, 60186, 78041, 78148
Required Accessories: Cat. #60186,78041,79796
This product is engineered on a CHO background (Human origin). The CHO host was selected for its compatibility with stable transfection and the target pathway or assay type. Consult the product datasheet for passage number guidance and recommended culture media.
This product is classified as BSL-1. Standard microbiological practices (gloves, lab coat, eye protection) are sufficient. No specialized containment facility is required beyond a clean bench. Consult your institutional IBC for GMO registration requirements.
Yes. The cell line has been screened using the MycoAlert™ Mycoplasma Detection kit (Lonza, #LT07-218) to confirm the absence of Mycoplasma species. We recommend that you independently confirm mycoplasma-negative status after receipt and periodically during routine culture using a validated detection kit.
Store this product at Liquid Nitrogen. Specifically: Cells will arrive upon dry ice and should immediately be thawed or stored in liquid nitrogen upon receipt. Do not use a -80°C freezer for long term storage. Transfer cells from dry-ice shipping to the recommended storage immediately upon receipt. Avoid repeated freeze-thaw cycles, which reduce viability and may alter expression characteristics.
Yes, a license is required (Yes). Purchase of this cell line grants a time-limited research-use license for use in your immediate laboratory only. This license does not permit redistribution, sub-licensing, transfer to other institutions, or commercial use. Refer to the License Disclosure section on this page or contact BPS Bioscience for details regarding modifications or commercial licensing.
This stable cell line was generated using Lipofectamine 2000 for transgene delivery into the parental host. The stably integrated cells were selected using the appropriate resistance marker and verified for expression prior to cryopreservation.
Can't find the cell line you need—or require a custom engineered model for your study? We offer end-to-end support for diverse research needs, including:
- Cell line sourcing and selection (species, tissue, and disease model matching)
- Stable cell line engineering (overexpression, knockdown, knockout via CRISPR/Cas9, shRNA, sgRNA)
- Reporter gene integration (GFP, RFP, luciferase, fluorescent/bioluminescent constructs)
- Genome editing and knockin (point mutations, tagged endogenous proteins, conditional alleles)
- Inducible expression systems (Tet-On/Off and regulatable constructs)
- Drug resistance marker selection (puromycin, G418, hygromycin, and others)
- Custom growth and media optimisation for specific assay requirements
- Scale-up production for high-throughput screening campaigns
- Authentication and QC services (STR profiling, mycoplasma testing, viability assessment)
Click Talk to a Scientist to submit a request form, email us at support@biohippo.com, or explore our Research Services for additional support. Our team will be in contact with you shortly.